Metastatic melanoma and matrix metalloproteinases

Gregory Riedlinger, Stephen Kridel, Ali M. Al-Housseini, Jennifer M. Brow, Thomas H. Bugge, Stephen H. Leppla, Nick Duesbery, George Vande Woude, Arthur Frankel

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Metastatic melanoma is a rapidly progressive, incurable malignancy for which novel therapies are needed. Analysis of the biology of melanoma cells reveals a dependency upon several critical pathways, with matrix metalloproteinases (MMPs) essential for tumor spread and dissemination. We describe a growing number of protein therapeutics which target melanoma cells by requiring activation by MMPs. These agents should have distinct side effects and may be useful in combinations with standard-cytotoxic chemotherapy or immunotherapies.

Original languageEnglish (US)
Pages (from-to)897-904
Number of pages8
JournalDrugs of the Future
Volume28
Issue number9
DOIs
StatePublished - Sep 2003

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Metastatic melanoma and matrix metalloproteinases'. Together they form a unique fingerprint.

  • Cite this

    Riedlinger, G., Kridel, S., Al-Housseini, A. M., Brow, J. M., Bugge, T. H., Leppla, S. H., Duesbery, N., Vande Woude, G., & Frankel, A. (2003). Metastatic melanoma and matrix metalloproteinases. Drugs of the Future, 28(9), 897-904. https://doi.org/10.1358/dof.2003.028.09.857377